Academic-industry partnerships in cannabis research are essential for generating the rigorous clinical evidence our field desperately needs. When established universities collaborate with licensed cannabis companies, it creates the infrastructure necessary for controlled studies that can inform evidence-based prescribing decisions.
Duquesne University has announced a research partnership with Terra Pharm, a cannabis company, to advance cannabis medicine research. This collaboration represents the growing trend of academic institutions partnering with industry to conduct controlled cannabis studies. Such partnerships are becoming increasingly important as traditional research barriers around cannabis continue to limit high-quality clinical trials and mechanistic studies.
“I’m encouraged to see more universities stepping into cannabis research partnerships — we need academic rigor applied to this medicine. The key will be ensuring these collaborations maintain scientific independence while leveraging industry resources and expertise.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What is the CED Clinical Relevance rating system?
The CED Clinical Relevance system appears to be a numbered classification that rates clinical findings or developments. Rating #70 indicates “Notable Clinical Interest” for emerging findings or policy developments that warrant close monitoring.
What type of research does this involve?
This involves cannabis-related research conducted through academic partnerships. The research focuses on evidence development and industry collaboration within the clinical cannabis field.
Who is conducting this research?
The research is being conducted by CED Clinic in collaboration with academic partners. This represents a partnership between clinical practice and academic institutions for cannabis research.
What makes this development noteworthy?
This development has been classified as having “Notable Clinical Interest” meaning it represents emerging findings or policy developments. The collaborative nature involving research, academic partnerships, and industry involvement makes it particularly significant.
What areas does this research cover?
The research encompasses multiple areas including clinical evidence development, academic research partnerships, and industry collaboration. The focus appears to be on advancing the clinical understanding and application of cannabis-based treatments.
